



쥐오줌풀 추출물이 MIA동물모델에서의 신경발달 단백질의 발현과 행동증상에 미치는 영향

원한솔*¹ · 김영옥**¹ · 이화영* · 임지윤* · 이상현*** · 조익현****
이상원** · 박춘근** · 김형기* · 권준택* · 김학재*[†]

*순천향대학교 의과대학 임상약리학교실, **농촌진흥청 국립원예특작과학원 인삼특작부,
중앙대학교 생명공학대학 식물시스템과학과, *경희대학교 한의과대학 융합의과학교실

Effect of *Valeriana fauriei* Extract on the Neurodevelopmental Proteins Expression and Behavioral Patterns in Maternal Immune Activation Animal Model

Hansol Won*¹, Young Ock Kim**¹, Hwayoung Lee*, Jiyun Im*, Sanghyun Lee***, Ik Hyun Cho****, Sang Won Lee**, Chun Geun Park**, Hyung Ki Kim*, Jun Tack Kwon* and Hak Jae Kim*[†]

*Department of Clinical Pharmacology, College of Medicine, Soonchunhyang University, Cheonan 31151, Korea.

**Development of Ginseng and Medical Plants Research Institute, NIHHS, RDA, Eumseong 27709, Korea.

***Department of Integrative Plant Science, Chungang University, Anseong 17546, Korea.

****Department of Convergence Medical Science, Brain Korea 21 Plus Program, and Institute of Korean Medicine, College of Oriental Medicine, Kyunghee University, Seoul 02453, Korea.

ABSTRACT

Background: Prenatal exposure to infectious and/or inflammatory insults can increase the risk of developing neuropsychiatric disorder such as bipolar disorder, autism, and schizophrenia later in life. We investigated whether *Valeriana fauriei* (VF) treatment alleviates prepulse inhibition (PPI) deficits and social interaction impairment induced by maternal immune activation (MIA).

Methods and Results: Pregnant mice were exposed to polyriboinosinic-polyribocytidilic acid (5 mg/kg, viral infection mimic) on gestational day 9. The adolescent offspring received daily oral treatment with VF (100 mg/kg) and injections of clozapine (5 mg/kg) for 30 days starting on the postnatal day 35. The effects of VF extract treatment on behavioral activity impairment and protein expression were investigated using the PPI analysis, forced swim test (FST), open field test (OFT), social interaction test (SIT), and immunohistochemistry. The MIA-induced offspring showed deficits in the PPI, FST, OFT, and SIT compared to their non MIA-induced counterparts. Treatment with the VF extract significantly recovered the sensorimotor gating deficits and partially recovered the aggressive behavior observed in the SIT. The VF extract also reversed the downregulation of protein expression induced by MIA in the medial prefrontal cortex.

Conclusions: Our results provide initial evidence of the fact that the VF extract could reverse MIA-induced behavioral impairment and prevent neurodevelopmental disorders such as schizophrenia.

Key Words: *Valeriana fauriei* Briq., Maternal Immune Activation, Polyriboinosinic-Polyribocytidilic Acid, Schizophrenia

INTRODUCTION

Valeriana fauriei Briq. (VF) has been used in humans

for hundreds of years (Liu *et al.*, 2012). This genus with over 250 species contains a variety of compounds, including valepotriates, valerenic acid, and its derivatives

¹Hansol Won and Young Ock Kim contributed equally to this paper.

[†]Corresponding author: (Phone) +82-41-570-2424 (E-mail) hak3962@sch.ac.kr

Received 2016 August 19 / 1st Revised 2016 September 20 / 2nd Revised 2016 October 5 / 3rd Revised 2016 October 10 / Accepted 2016 October 10

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

(Ahn *et al.*, 2012; Liu *et al.*, 2012). *Valeriana* has been used for people many years in China and Korea (Lee *et al.*, 2016b).

Valeriana genus has been used for centuries for treating epilepsy, myalgia, sleep disorders, and anxiety (Bent *et al.*, 2006). Many studies have shown its neuroprotective effect in *in vitro* models of Parkinson's disease. An aqueous extract of *Valeriana* has significant cytoprotective effect on rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells (de Oliveria *et al.*, 2009). Its anti-inflammatory properties as an inhibitor of NF- κ B has emerged from the knowledge of its traditional use as an anti-inflammatory remedy in Europe (Jacobo-Herrera *et al.*, 2006).

Miyasaka *et al.* (2006) have reported the efficacy and safety of valerian as a treatment option for anxiety disorders. In previous studies, the effects of VF on prenatal stress (PNS) offspring-related psychiatric disorders such as depression and schizophrenia were determined (Kang *et al.*, 2014; Lee *et al.*, 2016a). In addition, changes in protein levels and behavioral patterns were examined in the prefrontal cortex of PNS rats. We have revealed that the changes due to PNS are affected by VF treatment (Lee *et al.*, 2016a). Considering these data and the already known effects of VF on various diseases, we proposed that VF might be a target in the search for new agents to assist treatment for psychiatric disorders.

Therefore, the objective of this study was to determine the effect of VF administration on behavioral symptoms and the expression of neurodevelopmental proteins in a MIA model.

Maternal immune activation (MIA) due to infection during pregnancy has been repeatedly implicated in the etiology of developmental neuropsychiatric disorders, including bipolar disorder (Canetta *et al.*, 2014), autism (Brown *et al.*, 2014), and schizophrenia (Fatemi *et al.*, 2008). MIA can be induced by injecting pregnant dams with viral mimic polyriboinosinic - polyribocytidilic acid (Poly I:C), leading to a wide spectrum of schizophrenia-relevant functional and neuropathological deficits in adult offspring (Meyer *et al.*, 2010b).

Many MIA-induced behavioral, cognitive, and pharmacological dysfunctions in adult offspring are directly implicated in schizophrenia and other psychosis-related disorders, including abnormalities in sensorimotor gating,

selective attention, deficits in social interaction, working memory, and sensitivity to psychostimulant drugs (Bitanhirwe *et al.*, 2010).

In schizophrenia-like animal model induced by MIA, chronic antipsychotic drug treatment during periadolescence may prevent subsequent emergence of psychosis-related behavioral and pharmacological abnormalities in adulthood (Meyer *et al.*, 2010b). In addition, clozapine can effectively block phencyclidine-induced hyperlocomotion, improving the disruption of prepulse inhibition and deficits in social interaction (Bakshi *et al.*, 1994).

MATERIALS AND METHODS

1. Preparation of *Valeriana fauriei* extracts

The VF was obtained from a local farm in Jingbu province Republic of Korea. The roots of VF were air-dried avoiding sun-light and cut into small pieces for the experiment. The dried roots (2 kg) were soaked in 70% ethanol (3 ℓ) at room temperature for 1 day and extracted for 1 hour three times with 70% EtOH in an ultrasonic apparatus and filtered with filter paper (Advantec Toyo Kaisha Ltd., Tokyo, Japan) to remove the debris. The EtOH extract was evaporated under reduced pressure by rotary evaporator and lyophilized with freezing dryer to give 70% EtOH crude extract (330.2 g, yield 16.5%).

2. Animals

C57BL/6J mice (8 weeks old) were purchased from Central Lab Animal Inc. (Seoul, Korea). Mice were mated in groups of 1 male and 2 females. When a vaginal plug was observed during daily control, female mice were considered pregnant and separated. All mice were housed under standard conditions of a 12/12-h light/dark cycle (lights on at 06:30) with free access to food and water. All animal procedures were performed in accordance with the guidelines for the care and use of laboratory animals provided by the US National Institutes of Health (NRC, 1996).

3. Maternal immune activation and drug administration to mice

Clozapine (5 mg/kg/day, Sigma-Aldrich Co., St. Louis, MO, USA) was dissolved in acetic acid and diluted with saline followed by intraperitoneal injection. VF (100 mg/kg/

day) was dissolved in water and orally administered on postnatal day 35 for 4 weeks until postnatal day 65 (Meyer *et al.*, 2010b).

Pregnant dams on GD 9 received either a single injection of Poly I:C or CON (saline) solution via intravenous route at the tail vein under mild physical constraint. Poly I:C (potassium salt) was obtained from Sigma-Aldrich Co. (St. Louis, MO, USA) and dissolved in isotonic 0.9% NaCl solution to obtain the desired dosage (5 mg/kg calculated based on pure form of Poly I:C. All animals were returned to their home cages immediately after the injection procedure and left undisturbed until weaning of the offspring.

4. Behavioral tests

Modified behavioral tests, including forced-swim test (FST), open-field test (OFT), social interaction test (SIT), and prepulse inhibition (PPI) test, were performed as described previously (Lee *et al.*, 2016a).

1) Prepulse inhibition

An automated startle reflex system (SR Lab, San Diego Instruments, San Diego, CA, USA) was used to measure prepulse inhibition. This system consisted of a startle chamber housed in a sound attenuated isolation cabinet equipped with an internal fan and light. A cylindrical transparent acrylic holding apparatus resting on a four-pegged platform within the isolation chamber was used to hold each subject throughout the testing session.

Background noise and acoustic stimuli were controlled via the SR Lab microcomputer and interface assembly. They were delivered through a speaker mounted above the cylindrical holding apparatus. All test chambers were located in a sound attenuated experimental room to minimize external noise (Chang *et al.*, 2015). Background noise of 68 dB was present throughout the test session. After a 5 min acclimation period to the background noise, trials were presented in pseudorandom order, including 14 pulse alone trials in which a 40 ms, 120 dB broadband noise burst was presented, 30 prepulse + pulse trials in which the onset of a 20 ms broadband noise prepulse preceded the onset of the 120 dB pulse by 100 ms (10 for each of prepulse intensities of 3, 6, and 12 dB above the background noise, respectively), and eight non-stimulus trials consisting of only background noise. Prepulse intensities used in our

protocol did not induce startle reaction. All trials were presented with an average inter-trial interval of 22 s (15-30 s range). Four 120 dB pulse trials were presented at the beginning and the end of the test session with a series of 60 acoustic stimuli trials. However, they were not used in the calculation of PPI values.

The holding chambers were cleaned with 75% ethanol between each test session. The level of PPI was calculated as a percentage score for each prepulse using the following formula: %PPI = 100 - [(startle response for prepulse + pulse trial) / (startle response for pulse alone trial)] × 100 (Nozari *et al.*, 2015). Mean %PPI was considered as an overall measure of the observed treatment for which percent PPI data were averaged for three prepulses (Meyer *et al.*, 2010b).

2) Forced-swim test (FST)

FST was conducted as described previously (Adachi *et al.*, 2008). Mice were gently placed in a large transparent cylinder filled with fresh warm tap water (25 ± 2 °C) for 5 min. The water was changed between mice. The behaviors of swimming, climbing, and immobility were recorded with a video camera by an observer with a stopwatch.

3) Open-field test (OFT)

OFT was used to assess exploratory activity and reactivity to a novel environment. The test was carried out in clear opaque Plexiglas boxes (50 cm × 50 cm × 25 cm) equipped with a video as described previously (Cryan and Mombereau, 2004). Mice were placed in the center of the apparatus and their locomotor behaviors were recorded for 20 min. Horizontal locomotor activity was expressed as total ambulatory distance. The test box was cleaned with 70% ethanol between tests.

4) Social interaction test (SIT)

SIT was adapted from previous studies (Zhu *et al.*, 2014). Using the same open-field box, before the experiment, mice were placed in the environment for 30 min for acclimatization. SIT is commonly referred to as the behavior that occurs in a social context resulting from interaction between and among individuals (of the same species with equal body weight).

The behaviors of mice were recorded by a video camera placed above the arena. Social interaction included

the following behaviors; following or approaching the test partner, mounting or biting the test partner, sniffing or grooming any part of the body of the test partner. Each session lasted 20 min. Total duration of social play and the numbers and types of interactions were recorded.

5. Western blot

Medial prefrontal cortex (mPFC) tissues were lysed in RIPA buffer containing protease inhibitors followed by centrifugation at 14,000 rpm for 10 min at 4°C.

To detect dihydropyrimidinase-like 2 (Dpysl2) and neurofilament protein, 40 µg of lysed protein was subjected to 10 and 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Merck Millipore, Billerica, MA, USA). After blocking with 5% skim milk, membranes were probed with anti-Dpysl2 (1:1,000, Cell Signaling Technology Inc., Danvers, MA, USA), anti-LIM and SH protein 1 (Lasp1, 1:2,000, Merck Millipore, Billerica, MA, USA), anti-neurofilament M (Nefm, 1:1,000, Cell Signaling Technology Inc., Danvers, MA, USA), or anti-β-tubulin (Tubb, 1:3,000, Thermo Fisher Scientific Inc., Waltham, MA, USA) antibodies overnight at 4°C. After washing three times, membranes were then incubated with peroxidase-conjugated secondary anti-mouse (1:10,000, Sigma-Aldrich Co., St. Louis, MO, USA) or anti-rabbit (1:5,000, Abfrontier, Young In Frontier Co., Ltd., Seoul, Korea) for 1 h at room temperature. Immunoreactive bands were detected using an enhanced chemiluminescence kit (ELPIS-Biotech Inc., Daejeon, Korea). Quantitative measurements of Dpysl2, Lasp1, Nefm and Actb proteins were obtained using ImageJ software.

6. Immunohistochemistry

Mice were deeply anesthetized with ethyl ether and perfused with 4% paraformaldehyde. Fixed brains were removed, frozen, and cut into 30 µm sections. Frozen sections from mPFC were blocked with normal horse serum, incubated with anti-Dpysl2 (1:700, Atlas Antibodies AB, Stockholm, Sweden), Nefm (1:100, Cell Signaling Technology, Danvers, MA, USA), and anti-NeuN (1:100, Merck Millipore, Billerica, MA, USA) followed by incubation with Cy3-conjugated anti-rabbit and mouse secondary antibodies (1:500 and 1:800, Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA). Fluorescent images were captured

using a confocal laser-scanning microscope (FV10-ASW, Olympus Co., Tokyo, Japan). Images were quantified with Image J software using a protocol described previously with slight modifications (Kim *et al.*, 2015).

7. Statistical analysis

All data are expressed as mean ± standard deviation and/or standard error of the mean. They were compared using Student's *t*-test. All statistical analyses were performed using IBM SPSS statistics 22 software (SPSS Inc, Chicago, IL, USA). *p*-values <0.05 were considered as statistically significant.

RESULTS AND DISCUSSION

We used mouse MIA model to evaluate the extent to which the VF treatment altered the behavioral and protein expression that might be related to the pathophysiology of MIA-induced psychiatric disorders due to Poly I:C during pregnancy. We investigated the effects of VF treatment on MIA-induced behavioral phenotypes with PPI, FST, OFT, and SIT.

1. Prepulse inhibition

The effects of clozapine and VF on MIA-induced PPI deficits in mice are shown in Fig. 1.

We tested whether clozapine and VF treatment might be effective in preventing emergence of sensorimotor gating deficiency following MIA during adulthood. Sensorimotor gating was evaluated using the paradigm of PPI of acoustic startle reflex (ASR). Peripubertal clozapine and VF administration prevented the disruption of PPI in the offspring exposed to MIA (*p*<0.05, Fig. 1). Clozapine and VF administration also decreased ASR levels in MIA offspring (*p*<0.05, Fig. 1A).

Our results indicated that MIA significantly (*p*<0.05) altered PPI level at prepulse stimulus levels of 6, 9, and 12 dB above background between MIA offspring and control offspring. VF treatment significantly (*p*<0.05) elevated PPI trials scores in MIA offspring to levels found in control offspring (Fig. 1B). Poly I:C exposure to MIA affected (*p*<0.05) the reactivity to mean percent PPI (Fig. 1C). These results suggest that clozapine and VF can prevent the development of sensorimotor gating deficiency in MIA offspring.




Fig. 1. Prepulse inhibition (PPI) was analyzed in adult male mice exposed to MIA or male mice derived from litters without MIA exposure. PPI is presented as a mean present PPI value in startle amplitude as a function of the magnitude of prepulse stimulus using the following formula; mean present PPI = 100 - [(startle response for prepulse + pulse trial) / (startle response for pulse alone trial)] × 100]. Data are presented as means ± SEM (* $p < 0.05$ compared to CON, #,## $p < 0.05$ compared to MIA). CON; offspring of non-MIA mice, MIA; offspring of MIA mice, CLZ; offspring of MIA mice treated with clozapine drug, VF; offspring of MIA mice treated with *Valeriana fauriei* extract.

2. Forced swim test (FST)

We found significant differences in FST results among control, MIA, and VF-treated groups (Fig. 2). In particular, MIA offspring exhibited decrease in climbing but increase in immobility behaviors compared to control offspring ($p < 0.05$, Fig. 2). The changed behaviors were recovered after treatment with clozapine or VF ($p < 0.05$, Fig. 2).




Fig. 2. Behavioral response in forced-swim test. Comparison between offspring of the CON and MIA groups. A decrease in climbing activity was observed. Data are presented as means ± SEM (* $p < 0.05$ compared to CON, #,## $p < 0.05$ compared to MIA). CON; offspring of non-MIA mice, MIA; offspring of MIA mice, CLZ; offspring of MIA mice treated with clozapine drug, VF; offspring of MIA mice treated with *Valeriana fauriei* extract.

3. Open-field test (OFT)

Control and MIA offspring were subjected to OFT for 20 min. The MIA group had a significantly decrease in the number of line crossings and duration of rearing behaviors. These scores were recovered to their normal levels after treatment with clozapine or VF ($p < 0.05$, Table 1).

The MIA group showed a significantly increase in the number of cage sniffing and immobility behaviors. These scores were also recovered to their normal level after treatment with clozapine or VF ($p < 0.05$, Table 1). However, the MIA offspring did not show significant difference in central entries, number of rearing behaviors, or the duration of cage sniffing compared to control offspring ($p > 0.05$, Table 1).

4. Social interaction test (SIT)

MIA also induced severe social deficits (Table 2). Scores of most aggressive behaviors (aggressive grooming the partner, biting the partner) during SIT were increased significantly in the MIA group compared to those in the control group. These scores were decreased to normal levels after treatment with clozapine or VF ($p < 0.05$, Table 2).

On the other hand, reductions in sniffing the partner

Table 1. Behavior of CON and MIA and clozapine treatment of MIA and *Valeriana fauriei* extract treatment of MIA in an open field test.

	CON	MIA	CLZ	VF
Central entered*	31.44 ± 3.35	15.56 ± 2.09	19.00 ± 2.84	20.44 ± 2.43
Line crossing* ^{*,#,#}	09.78 ± 0.91	3.33 ± 0.44	7.33 ± 1.26	10.44 ± 1.33
Run (n)	0.11 ± 0.11	0.22 ± 0.22	0.22 ± 0.15	0.00 ± 0.00
Run (s)	0.22 ± 0.22	0.33 ± 0.33	0.56 ± 0.38	0.00 ± 0.00
Rear (n)*	117.56 ± 4.16	79.89 ± 6.79	79.33 ± 6.87	97.44 ± 8.42
Rear (s)* ^{*,#}	245.67 ± 9.36	155.00 ± 15.03	153.22 ± 14.99	212.00 ± 19.48
Grooming (n)	6.89 ± 0.92	5.11 ± 1.01	5.00 ± 0.83	4.00 ± 0.62
Grooming (s)	42.56 ± 3.37	30.22 ± 6.76	31.89 ± 4.37	31.00 ± 5.86
Cage sniff (n) ^{*,#}	179.44 ± 7.04	166.11 ± 15.88	89.11 ± 9.23	115.56 ± 8.22
Cage sniff (s)	524.67 ± 25.43	447.00 ± 35.84	374.56 ± 53.45	429.44 ± 36.57
Immobile (n) ^{*,#,#}	3.22 ± 1.10	85.33 ± 10.16	19.11 ± 3.88	1.56 ± 0.53
Immobile (s) ^{*,#,#}	7.89 ± 2.75	238.44 ± 40.38	25.33 ± 4.94	5.33 ± 1.56

Data are presented as mean ± SEM, n; number of the behavior, s; duration measured in seconds, CON; non-Poly I:C-injection group, MIA; Poly I:C-injection group, CLZ; intraperitoneal injection with clozapine of Poly I:C-injection group, VF; administration with *Valeriana fauriei* extract of Poly I:C-injection group, *; between CON and MIA p -value < 0.05, #; between MIA and CLZ p -value < 0.05, ##; between MIA and VF p -value < 0.05.

Table 2. Behavior of CON and MIA and clozapine treatment of MIA and *Valeriana fauriei* extract treatment of MIA in a social interaction test.

	CON	MIA	CLZ	VF
Sniffing (n)* ^{*,#}	93.83 ± 3.70	60.08 ± 3.37	74.92 ± 2.39	63.25 ± 2.43
Sniffing (s)* ^{*,#,#}	152.25 ± 6.02	97.08 ± 4.61	154.00 ± 16.46	122.42 ± 7.42
Following (n)	3.50 ± 0.82	9.83 ± 5.60	7.08 ± 1.19	5.17 ± 0.82
Following (s)	9.08 ± 2.28	8.67 ± 1.55	14.92 ± 3.19	14.25 ± 2.34
Grooming the partner (n) ^{*,#}	1.08 ± 0.38	0.33 ± 0.19	0.50 ± 0.29	5.50 ± 2.14
Grooming the partner (s) ^{*,#}	6.33 ± 2.82	1.83 ± 1.09	2.42 ± 1.29	18.33 ± 7.10
Fight (n)	0.00 ± 0.00	0.33 ± 0.26	0.00 ± 0.00	0.00 ± 0.00
Fight (s)	0.00 ± 0.00	0.67 ± 0.51	0.00 ± 0.00	0.00 ± 0.00
Aggressive grooming (n) ^{*,#,#}	0.08 ± 0.08	1.08 ± 0.40	0.08 ± 0.08	0.00 ± 0.00
Aggressive grooming (s) ^{*,#,#}	0.17 ± 0.17	3.00 ± 1.20	0.58 ± 0.58	0.00 ± 0.00
Biting (n) ^{*,#,#}	2.58 ± 0.62	6.00 ± 1.36	0.17 ± 0.11	2.42 ± 0.96
Biting (s) ^{*,#,#}	10.00 ± 3.34	19.08 ± 5.12	0.58 ± 0.43	6.08 ± 2.39

Data are presented as mean ± SEM, n; number of the behavior, s; duration measured in seconds, CON; non-Poly I:C-injection group, MIA; Poly I:C-injection group, CLZ; intraperitoneal injection with clozapine of Poly I:C-injection group, VF; administration with *Valeriana fauriei* extract of Poly I:C-injection group, *; between CON and MIA p -value < 0.05, #; between MIA and CLZ p -value < 0.05, ##; between MIA and VF p -value < 0.05.

and grooming the partner induced by MIA were rescued by treatment with VF. These results indicate that VF can ameliorate defective social interactions in MIA-induced animal model ($p < 0.05$, Table 2).

5. Western blot and immunohistochemistry

Our previous studies have shown that Lasp1 and Dpysl2 are regulated in prefrontal cortex in schizophrenia-like animal model (Joo *et al.*, 2013; Lee *et al.*, 2015).

To investigate MIA-induced downregulation of several

neurodevelopmental proteins such as Lasp1, Dpysl2, and Nefm proteins, we performed Western blotting and immunohistochemical analyses (Fig. 3, 4, 5) of the mPFC areas from control, MIA, clozapine, and VF administered offspring brains. Western blot results revealed that the quantities of these three proteins in the mPFC area of the MIA group were significantly lower than those in the control group ($p < 0.05$, Fig. 3). These changes were restored by clozapine or VF treatment ($p < 0.05$, Fig. 3). Immunofluorescent-stained brain images revealed that

Dpysl2 and Nefm were differentially expressed among control, MIA, clozapine treated, and VF treated groups with significant differences in staining intensity value ($p < 0.05$, Fig. 4, 5).

The genus *Valeriana* contains over 250 species including subspecies such as *Valeriana fauriei* Briq. (VF) and *Valeriana officinalis* (Circosta *et al.*, 2007). Several previous studies have shown that VF might improve sleep quality (Bent *et al.*, 2006). The effects of VF on spatial memory have been demonstrated using a novel object recognition and water maze test (Nam *et al.*, 2013).

VF also has antioxidant effects and antidepressant-like activity (Liu *et al.*, 2012). Additionally, *in vitro* study has shown that *Valeriana officinalis* extract has neuroprotective properties against A β toxicity (Malva *et al.*, 2004). In this study, we proposed that VF might be able to reverse schizophrenia-like behavior in MIA offspring using an animal model.

Using an epidemiologically motivated neurodevelopmental animal model of related psychiatric disorders such as depression and schizophrenia, previous studies showed that MIA in the form of viral-like acute phase response can trigger early/middle gestation (GD9) in mice, leading to long-lasting changes in behavior and protein expression (Meyer *et al.*, 2010b). Impaired social interaction behavior was also observed in MIA offspring. This diminution in social interaction behaviors could reflect an increase in anxiety in MIA offspring (Bitanirwe *et al.*, 2010). The influence of MIA is consistent with previous reports on social interaction deficits emerged in adult mice after exposing to Poly I:C in middle gestation (Smith *et al.*, 2007). In this current study, MIA-induced increases in aggressive behavior were restored by VF treatment. In addition, some behavioral patterns in FST and OFT were recovered by the treatment.

We found PPI deficits in the offspring of MIA treated by synthetic double-stranded RNA poly I:C. Braff *et al.* (2001) have shown deficits in the PPI of the startle response in both schizophrenic patients and animal models of this disorder (Braff *et al.*, 2001). Such deficits in PPI are believed to reflect disruption in sensorimotor gating. We also found that exposure to MIA disrupted the gating as reflected by deficits in PPI and the deficit may be affected by VF treatment. Clozapine antipsychotic is well-known to be effective in treating positive and negative




Fig. 3. Western blot analysis of Dpysl2, Lasp1, and Nefm expression in the brains of MIA-induced mice. (A); mice exposed to maternal immune activation (MIA) exhibited decreased Lasp1 expression in the medial prefrontal cortex. Lasp1 expression showed a significant difference in Lasp1 levels between MIA treated and VF-treated groups. (B); mice exposed to maternal immune activation (MIA) exhibited decreased Dpysl2 expression in the medial prefrontal cortex. Dpysl2 expression showed significant difference in Dpysl2 levels between MIA treated and VF-treated groups. (C); mice exposed to maternal immune activation (MIA) exhibited decreased Nefm expression in the medial prefrontal cortex. Nefm expression showed significant difference in Nefm levels between MIA treated and VF-treated groups (* $p < 0.05$ compared to the CON group in the medial prefrontal cortex, ## $p < 0.05$ compared to MIA group in the medial prefrontal cortex). CON; offspring of non-MIA mice, MIA; offspring of MIA mice, CLZ; offspring of MIA mice treated with clozapine drug, VF; offspring of MIA mice treated with *Valeriana fauriei* extract.




Fig. 4. Immunohistochemical analysis of Dpysl2 expression in the brains of MIA-induced mice. (A); confocal microscopic image showing immunofluorescent staining for Dpysl2 (anti-Dpysl2, red, Cy3) with NeuN in the medial prefrontal cortex. Fluorescent staining revealed a decrease of Dpysl2 in these regions. Scale bar, mPFC, 50 μ m. (B); scatter gram in the graph indicates SEM (* $p < 0.05$ compared to CON, ## $p < 0.05$ compared to MIA). mPFC; medial frontal cortex, CON; offspring of non-MIA mice, MIA; offspring of MIA mice, CLZ; offspring of MIA mice treated with clozapine drug, VF; offspring of MIA mice treated with *Valeriana fauriei* extract, SEM; Standard error of the mean.




Fig. 5. Immunohistochemical analysis of Nefm expression in the brains of MIA-induced mice. (A); confocal microscopic image showing immunofluorescent staining for Nefm (anti-Nefm, green, FITC) with DAPI (blue) in the medial prefrontal cortex. Fluorescent staining revealed a decrease of Dpysl2 in these regions. Scale bar, mPFC, 50 μ m. (B); the scatter gram in the graph indicates SEM (* $p < 0.05$ compared to CON, ## $p < 0.05$ compared to MIA). mPFC; medial frontal cortex, CON; offspring of non-MIA mice, MIA; offspring of MIA mice, CLZ; offspring of MIA mice treated with clozapine drug, VF; offspring of MIA mice treated with *Valeriana fauriei* extract, SEM; Standard error of the mean.

symptoms of schizophrenia (Manschreck *et al.*, 1999) or reverse PPI disruption induced by MIA in offspring (Meyer *et al.*, 2010a). The efficacy of clozapine has been attributed to its action on several different mPFC neurotransmitter systems (Johnston-Wilson *et al.*, 2000).

In the present study, the typical antipsychotic clozapine was effective in restoring PPI deficits observed in MIA offspring treated with Poly I:C during pregnancy.

In this study, we investigated the levels of two proteins; Dpysl2 and neurofilament protein. The decrease of mPFC in neurofilament and Dpysl2 proteins due to MIA was affected by VF treatment. Dpysl2, also known as collapsin response mediator protein 2, can regulate axonal outgrowth by promoting microtubule assembly, vesicle trafficking, and synaptic physiology (Lin *et al.*, 2011). The expression of Dpysl2 in humans has been reported to be decreased in the brains of patients with schizophrenia (Johnston-Wilson *et al.*, 2000).

Neurofilament protein may also play a role in intracellular transport to axons and dendrites. It forms part of the axon skeleton and functionally maintains neuronal caliber (Cassereau *et al.*, 2013). Our previous study has shown that Dpysl2 and neurofilament protein levels are decreased in stress-induced schizophrenia-like rat offspring but recovered by VF treatment (Lee *et al.*, 2016a). These findings suggest that changes in the expression of neurodevelopmental proteins such as neurofilament proteins and Dpysl2 caused by MIA might have enduring effects on axonal outgrowth and synaptic function in MIA offspring.

Our results showed that maternal administration of Poly I:C into MIA caused abnormality of behavioral pattern, deficits in sensory-motor gating, and aggressive behavior in SIT. However, these effects could be improved by oral administration extract of VF. Some behavioral patterns in FST and OFT for the analysis of depressive behaviors were recovered by treatment with VF.

In addition, MIA-induced decrease in the expression levels of neurofilament and Dpysl2 was restored to normal levels after treatment with VF. The present study provided valuable data regarding additional role of VF in addressing the pathogenesis of psychiatric disorders such as schizophrenia. However, further research is needed to characterize the pharmacological functions of VF using cellular and animal models.

ACKNOWLEDGEMENTS

This work was carried out with the support of Cooperative Research Program for Agriculture Science and Technology Development(PJ011582) Rural Development Administration, Republic of Korea.

REFERENCES

- Adachi M, Barrot M, Autry AE, Theobald D and Monteggia LM.** (2008). Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. *Biological Psychiatry*. 63:642-649.
- Ahn YS, Hur M, An TJ, Park CG, Kim YG, Park CB and Baek WS.** (2012). Study on flowering, bearing fruit, seed harvesting and seedling transplanting cultivation of *Valeriana fauriei* Briquet. *Korean Journal of Medicinal Crop Science*. 20:365-371.
- Bakshi VP, Swerdlow NR and Geyer MA.** (1994). Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. *Journal of Pharmacology and Experimental Therapeutics*. 271:787-794.
- Bent S, Padula A, Moore D, Patterson M and Mehling W.** (2006). Valerian for sleep: A systematic review and meta-analysis. *American Journal of Medicine*. 119:1005-1012.
- Bitanhirwe BK, Peleg-Raibstein D, Mouttet F, Feldon J and Meyer U.** (2010). Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. *Neuropsychopharmacology*. 35:2462-2478.
- Braff DL, Geyer MA and Swerdlow NR.** (2001). Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. *Psychopharmacology*. 156:234-258.
- Brown AS, Sourander A, Hinkka-Yli-Salomki S, McKeague IW, Sundvall J and Surcel HM.** (2014). Elevated maternal C-reactive protein and autism in a national birth cohort. *Molecular Psychiatry*. 19:259-264.
- Canetta S, Sourander A, Surcel HM, Hinkka-Yli-Salomki S, Leivisk J, Kellendonk C, McKeague IW and Brown AS.** (2014). Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort. *American Journal of Psychiatry*. 171:960-968.
- Cassereau J, Nicolas G, Lonchampt P, Pinier M, Barthelaix A, Eyer J and Letournel F.** (2013). Axonal regeneration is compromised in NFH-LacZ transgenic mice but not in NFH-GFP mice. *Neuroscience*. 228:101-108.
- Chang CH, Hsiao YH, Chen YW, Yu YJ and Gean PW.** (2015). Social isolation-induced increase in NMDA receptors in the hippocampus exacerbates emotional dysregulation in mice. *Hippocampus*. 25:474-485.
- Circosta C, De Pasquale R, Samperi S, Pino A and Occhiuto F.** (2007). Biological and analytical characterization of two extracts from *Valeriana officinalis*. *Journal of Ethnopharmacology*. 112:361-367.
- Cryan JF and Mombereau C.** (2004). In search of a depressed

- mouse: Utility of models for studying depression-related behavior in genetically modified mice. *Molecular Psychiatry*. 9:326-357.
- de Oliveria DM, Barreto G, De Andrade DV, Saraceno E, Aon-Bertolino L, Capani F, Bachá RDSE and Giraldez LD.** (2009). Cytoprotective effect of *Valeriana officinalis* extract on an *in vitro* experimental model of Parkinson disease. *Neurochemical Research*. 34:215-220.
- Fatemi SH, Reutiman TJ, Folsom TD, Huang H, Oishi K, Mori S, Smee DF, Pearce DA, Winter C, Sohr R and Juckel G.** (2008). Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: Implications for genesis of neurodevelopmental disorders. *Schizophrenia Research*. 99:56-70.
- Jacobo-Herrera NJ, Vartiainen N, Bremner P, Gibbons S, Koistinaho J and Heinrich M.** (2006). NF- κ B modulators from *Valeriana officinalis*. *Phytotherapy Research*. 20:917-919.
- Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF and Yolken RH.** (2000). Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. *Molecular Psychiatry*. 5:142-149.
- Joo J, Lee S, Nah SS, Kim YO, Kim DS, Shim SH, Hwangbo Y, Kim HK, Kwon JT, Kim JW, Song HY and Kim HJ.** (2013). *Laspl* is down-regulated in NMDA receptor antagonist-treated mice and implicated in human schizophrenia susceptibility. *Journal of Psychiatric Research*. 47:105-112.
- Kang MG, Kim YH, Im AR, Nam BS, Chae SW and Lee MY.** (2014). Antidepressant-like effects of *Schisandra chinensis* Baillon water extract on animal model induced by chronic mild stress. *Korean Journal of Medicinal Crop Science*. 22:196-202.
- Kim YO, Lee HY, Won H, Nah SS, Lee HY, Kim HK, Kwon JT and Kim HJ.** (2015). Influence of *Panax ginseng* on the offspring of adult rats exposed to prenatal stress. *International Journal of Molecular Medicine*. 35:103-109.
- Lee H, Joo J, Nah SS, Kim JW, Kim HK, Kwon JT, Lee HY, Kim YO and Kim HJ.** (2015). Changes in *Dpysl2* expression are associated with prenatally stressed rat offspring and susceptibility to schizophrenia in humans. *International Journal of Molecular Medicine*. 35:1574-1586.
- Lee H, Won H, Im J, Kim YO, Lee S, Cho IH, Kim HK, Kwon JT and Kim HJ.** (2016a). Effect of *Valeriana fauriei* extract on the offspring of adult rats exposed to prenatal stress. *International Journal of Molecular Medicine*. 38:251-258.
- Lee YS, Lee SW, Kim YB, Kim OT, Park KH, Lee JW, Lee DY, Kim GS, Kwon DY and Han SH.** (2016b). Monitoring of biological hazards in herbal crops from Korean market. *Korean Journal of Medicinal Crop Science*. 24:143-151.
- Lin PC, Chan PM, Hall C and Manser E.** (2011). Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein (MAP) that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction. *Journal of Biological Chemistry*. 286:41466-41478.
- Liu XG, Gao PY, Wang GS, Song SJ, Li LZ, Li X, Yao XS and Zhang ZX.** (2012). *In vivo* antidepressant activity of sesquiterpenes from the roots of *Valeriana fauriei* Briq. *Fitoterapia*. 83:599-603.
- Malva JO, Santos S and Macedo T.** (2004). Neuroprotective properties of *Valeriana officinalis* extracts. *Neurotoxicity Research*. 6:131-140.
- Manschreck TC, Redmond DA, Candela SF and Maher BA.** (1999). Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 11:481-489.
- Meyer U, Knuesel I, Nyffeler M and Feldon J.** (2010a). Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. *Psychopharmacology*. 208:531-543.
- Meyer U, Spoerri E, Yee BK, Schwarz MJ and Feldon J.** (2010b). Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. *Schizophrenia Bulletin*. 36:607-623.
- Miyasaka LS, Atallah N and Soares B.** (2006). Valerian for anxiety disorders. *Cochrane Database of Systematic Reviews*. John Wiley and Sons, Ltd. Chichester, England. 18:CD004515. [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004515.pub2/pdf/cited by 2016 May 20](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004515.pub2/pdf/cited%20by%202016%20May%2020).
- Nam SM, Choi JH, Yoo DY, Kim W, Jung HY, Kim JW, Kang SY, Park J, Kim DW, Kim WJ, Yoon YS and Hwang IK.** (2013). *Valeriana officinalis* extract and its main component, valerenic acid, ameliorate D-galactose-induced reductions in memory, cell proliferation, and neuroblast differentiation by reducing corticosterone levels and lipid peroxidation. *Experimental Gerontology*. 48:1369-1377.
- National Research Council(NRC).** (1996). Guide for the care and use of laboratory animals. National Academy Press. Washington, DC, USA. p.22.
- Nozari M, Shabani M, Farhangi AM, Mazhari S and Atapour N.** (2015). Sex-specific restoration of MK-801-induced sensorimotor gating deficit by environmental enrichment. *Neuroscience*. 299:28-34.
- Smith SE, Li J, Garbett K, Mirnics K and Patterson PH.** (2007). Maternal immune activation alters fetal brain development through interleukin-6. *Journal of Neuroscience*. 27:10695-10702.
- Zhu F, Zheng Y, Liu Y, Zhang X and Zhao J.** (2014). Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic-polyribocytidilic acid. *Psychiatry Research*. 219:680-686.